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1  
ABSTRACT 
This report describes the preparation, homogeneity, stability and certification studies of a 
freeze-dried salmon tissue (BCR-725) certified for its contents of flumequine and oxolinic 
acid. A description of the analytical procedures used in the homogeneity and stability studies 
as well as in the certification study is included. All individual results of the certification study 
are reported. All relevant data from the homogeneity and stability studies and certification 
measurements are presented. 
The certified values (expressed on dry mass basis) are: 
 
Substance Certified value 
[µg/kg] 
Uncertainty* 
[µg/kg] 
Flumequine 1170 210 
Oxolinic acid 600 100 
* combined uncertainty with a coverage factor k = 2 
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1. INTRODUCTION 
1.1 Background: need for a CRM 
The quinolones group includes flumequine and oxolinic acid, which are used in aquaculture. 
Both compounds are active at low doses and only slightly metabolized. 
Flumequine is a first generation quinolone. In aquaculture, flumequine is especially used 
against furunculosis, enteric redmouth disease and pseudotuberculosis. The oral absorption in 
fish is rather good, a bioavailability from medicated feed on 60-80% is reported. Flumequine 
seems to be less used in Europe than oxytetracycline and oxolinic acid, but the use is increas-
ing. 
Oxolinic acid is an older member of the group of synthetic antimicrobial agents generically 
termed the quinolones. The compound is particularly active against Gram-negative bacteria 
including fish pathogens which cause diseases like enteric redmouth disease, furunculosis, 
cold-water vibriosis and classic vibriosis. Because of its effectiveness and relatively modest 
cost it has become one of the most widely used drugs in aquaculture. The absorption from 
medicated fish in seawater is about 20%. In freshwater the bioavailability is somewhat higher. 
Flumequine is included in annex 1 of Council Regulation (EEC) No. 2377/90 for salmon spe-
cies in muscle and skin in a natural proportion with a maximum residue limit (MRL) of 600 
µg/kg. 
Oxolinic acid is included in annex 1 of Council Regulation (EEC) No. 2377/90 for fish and 
fins in muscle and skin in a natural proportion with MRL of 100 µg/kg. At the date of the 
production of the certified reference material, a temporary MRL was established to 300 
µg/kg. 
Analytical procedures for determining flumequine and oxolinic acid in fish tissue involve 
extractions and chromatography. Quality and verification of all steps in the analytical proce-
dures require the availability of a matrix reference material. BCR-725 has been produced for 
this purpose. The property values of flumequine and oxolinic acid in the freeze-dried fish tis-
sue were chosen to be higher than the MRL values. The structures of the two quinolones are 
shown in fig. 1.  
 
   FLUMEQUINE    OXOLINIC ACID 
    [42835-25-6]        [14698-29-4]    
 
Figure 1 - Structures of the target compounds and CAS-numbers. 
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1.2 Choice of the material to be certified 
Flumequine and oxolinic acid are not usually simultaneously employed for fish treatment in 
aquaculture, therefore it is unlikely to find both compounds within the same salmon fish tis-
sue. However one single CRM was finally produced and bottled, as freeze-dried salmon tis-
sue, since the two quinolones can easily be determined using the same analytical procedure.  
Salmon fish was treated with flumequine and oxolinic acid, respectively. Muscle tissue plus 
skin was blended in natural proportions, and non-medicated tissue plus skin was added to 
obtain the contamination level desired. After throughly blending and mixing the material was 
freeze-dried. Non-medicated tissue ensured zero blank values.  
Water content in fresh fish is approximately 70% w/w. As laboratories usually analyse fresh 
fish, the water content has to be taken into account. The certified values are given on the basis 
of dry matter. 
 
1.3 Design of the project and certification procedure 
Preparation of medicated fish and procedures for blending, mixing and freeze-drying were 
developed in a feasibility trial. A test batch was produced and used for preliminary homoge-
neity and stability studies as well as for training and testing the candidate laboratories for the 
certification measurements. Details are given in section 3. 
Approximately 3.2 kilos of freeze-dried tissue with slightly different target values were pre-
pared and sent to IRMM for final freeze-drying and bottling of 1400 samples with 2.2 g of 
material each. Random samples were used for homogeneity testing, stability testing and the 
certification measurements. Details are given in sections 4-7. 
Before the training exercise, standard solutions of both quinolones were supplied to each 
laboratory to verify their calibration procedure. Vials with known contents of both quinolones 
were supplied together with the samples for certification measurements. 
 
2. PARTICIPANTS 
 
Preparation of medicated and not medicated salmon 
- Nutreco A/S, Stavanger         NO 
 
Feasibility study, preparation of freeze-dried tissue 
- Norwegian College of Veterinary Medicine, NCVM     NO 
 
Final homogenization and bottling of glass vials 
- Institute for Reference Materials and Measurements, IRMM    BE 
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Homogeneity and stability studies 
- Danish Technological Institute, DTI       DK 
 
Certification measurements 
- AFSSA Fougères         FR 
- Danish Veterinary and Food Administration, IFSE     DK 
- Danish Technological Institute, DTI       DK 
- Ecole Nationale Vétérinaire de Nantes       FR 
- Institute for Reference Materials and Measurements, IRMM    BE 
- Ministerio de Sanidad y Consumo, Instituto de  Salud Carlos III   ES 
- National Food Administration, Chemistry Division 3     SE 
- National Veterinary and Food Research Institute, Dept. of Chemistry  FI 
- Niedersächsisches Landesamt für Verbraucherschutz & Lebensmittelsicherheit DE 
- Norwegian College of Veterinary Medicine, NCVM                           NO      
- Universitat de Barcelona        ES 
- Wetenschapelijk Instituut Volksgezondheid - Louis Pasteur, Dept. Voedingswaren BE 
 
Statistical evaluation and uncertainties 
- Danish Technological Institute, DTI       DK 
- Institute for Reference Materials and Measurements, IRMM    BE 
 
3. FEASIBILITY STUDY 
3.1 General 
The certification of the reference material was preceded by an extensive feasibility study per-
formed both on the material preparation and the ability of the participants to measure the sub-
stances of interest. 
The preparation of a homogeneous muscle tissue material was not a difficult task, but inclu-
sion of the skin in a natural proportion presented problems. It was not possible just to blend 
muscle plus skin. After several attempts, the procedure described in section 4.1 was devel-
oped. 
Analytical methods published so far describe the determination of the quinolones in muscle 
tissue. A method involving a clean-up step with organic solvents [1] and a fast direct method 
[2] are described. Both approaches, developed by Yndestad and co-workers at the Norwegian 
College of Veterinary Medicine (NCVM), permit the extraction of the quinolones into a liquid 
phase in a few minutes. In addition to the work to produce a homogeneous mixture of tissue 
and skin, NCVM also investigated the extraction of quinolones from skin. Such study, which 
presents more difficulties than extraction from muscle, ended up on the development of a di-
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rect method avoiding any clean-up step with organic solvents [3]. All methods were presented 
to the participating laboratories. 
Analytical work for homogeneity and stability tests was done using the method described in 
[1]. Water content in the freeze-dried material was ignored in the feasibility study. 
 
3.2 First preliminary interlaboratory study 
The experiments including blending, mixing and freeze-drying muscle plus skin tissues gave 
as a result a portion containing 30-40 g of freeze-dried material. One vial containing 1 g of 
material was delivered to each laboratory, so they could become familiar with the freeze-dried 
material. The freeze-dried material, reconstituted by mixing 2 mL of water with 1 g of the 
powder resembled blended fresh fish. Methods [1], [2] and [3] describe the analysis of fresh 
tissue. 
In addition to the sample, two vials containing blank fish and spiked fish extract, respectively, 
were delivered to the participant laboratories. Freeze-dried blank fish was produced from non-
medicated salmon. For the production of spiked extract several portions of extract were made 
according to [3] using non-medicated salmon. The extracts were mixed, and spiked with qui-
nolones up to a final concentration of 12 ng/mL flumequine and 24 ng/mL oxolinic acid. 
 
3.3 Results from first preliminary interlaboratory study 
Homogeneity test carried out on 6 vials prior to the study was satisfactory, RSD < 3%. Most 
of the participating laboratories analysed the freeze-dried fish sample either using extraction 
of the quinolones [2] followed by direct measurements by HPLC with fluorescence detection, 
or carrying out a clean-up step with organic solvents before the chromatographic stage. A 
number of laboratories used their own methods, different from those already described. 
Excluding very deviating results from two laboratories, the mean ± mean standard deviation 
of the remaining results were: 
 
- Flumequine:  351 µg/kg ± 45 µg/kg (RSD = 13%); 
- Oxolinic acid : 849 µg/kg ± 102 µg/kg (RSD = 12%). 
 
A rough division between methods gave two groups: 
 
- Group I:   Methods using extraction at pH > 9 and simple clean-up of the water phase; 
- Group II: Methods using extractions involving organic solvents and evaporation. 
 
Methods in Group I demand close matching of the whole analytical procedure and the calibra-
tion procedure as mentioned in the NCVM method [2]. Personnel must have experience with 
the applied method and use it frequently. The addition of quinolones to a sample of blank fish 
is necessary for calibration, and it is important to ensure complete mixing with the fish mate-
rial before extraction. 
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Methods in Group II are more labour work consuming, but may be more robust. It is easier to 
obtain the same conditions for analysis and calibration at the chromatographic stage. 
In most cases the signals corresponding to oxolinic acid and flumequine in blank fish samples 
were below the limit of detection of the technique employed. 
Results from analyses of spiked extracts were generally good, but many participants reported 
the presence of interfering peaks. Sometimes these peaks could be resolved from oxolinic acid 
and flumequine peaks, but that was not always the case. The origin of these peaks is not clear 
– they could be attributed to degradation products. 
 
3.4 Second preliminary interlaboratory study 
Approximately 300 vials with 1.2 g of freeze-dried material were produced using the proce-
dure described in section 4.1, followed by bottling into vials. 30 vials with blank freeze-dried 
material were prepared analogously. 
Due to instability problems, vials with spiked extracts were not prepared. It was instead de-
cided to prepare vials with evaporated spiked extracts. An extract was made as described in 
section 3.2, and the quinolones were extracted with trichloromethane. 1.00 mL CHCl3 was 
transferred to vials, and the CHCl3 evaporated. The laboratories were instructed to add their 
normal mobile HPLC phase to the vial, mix throughly and inject into the HPLC system. 
Before distribution of the vials to the participating laboratories, homogeneity tests were car-
ried out on 10 vials containing fish material and 6 vials containing evaporated spiked extract. 
The results of the test indicated negligible inhomogeneity between the units. 
When the production was finished, a stability test was initiated, using 41 vials with fish mate-
rial chosen at random. Vials were successively transferred from the storage temperature to     
–80 °C. After 150 days all vials were analysed using repeatability conditions. No significant 
(95% and 99%) alteration was found during 150 days’ storage at –18 °C, +4 °C and ambient 
temperature, respectively. 
 
3.5 Results from second preliminary interlaboratory study 
The laboratories were requested to analyse 12 vials with freeze-dried material on 5 different 
days, in order to calculate the RSD within days and RSD between days. 
RSD within days > 15 % and RSD between days > 20 % were considered not acceptable. 14 
out of 18 laboratories submitted acceptable results. 
10 laboratories used extraction involving clean-up step with organic solvent. One laboratory 
used MS for detection. No difference was observed between different extraction procedures 
and detection modes. 
The laboratory detecting with MS did not get any improvement using nalidixic acid as inter-
nal standard. Nalidixic acid behaved differently from flumequine and oxolinic acid. The out-
come of the calculations on all laboratory results is shown in table 1. 
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Table 1- Summary of second preliminary intercomparison study results 
for contaminated freeze-dried material. 
 Flumequine Oxolinic acid 
Overall mean, µg/kg 303 537 
RSD of overall mean 7.4 7.9 
Mean RSD, within days 4.3 3.2 
Mean RSD, between days 5.9 4.3 
Mean recovery, % 79 83 
 
In most cases the signals corresponding to oxolinic acid and flumequine in blank fish samples 
were below the limit of detection of the technique employed.  
Many laboratories reported values close to the detection limits for the evaporated spiked ex-
tract samples.  
 
3.6 Concluding remarks 
The feasibility study demonstrated the suitability of the procedure developed for the produc-
tion of homogeneous contaminated freeze-dried material of muscle and skin in natural propor-
tions. Furthermore, extraction of the quinolones from fish material was investigated, and the 
results implemented in analytical methods at all participating laboratories. Essential prerequi-
sites for a successful preparation and certification of a candidate CRM were provided. The 
feasibility study took more time and resources than planned in the project schedule, which 
originally did not foresee the inclusion of skin. 
 
4. PREPARATION OF THE MATERIAL 
4.1 Preparation of the homogenized batch 
Breeding of salmon medicated with flumequine and oxolinic acid, respectively, together with 
unmedicated salmon was done at Nutreco A/S, Stavanger, Norway. In frozen condition they 
were brought to NCVM in Oslo, where the fish was analysed using the method described in 
[3]. 
Analyses of fish treated with oxolinic acid and analyses of fish treated with flumequine were 
carried out. On the basis of the results the average values of the two substances in muscula-
ture, including skin, were calculated. In addition, analyses of untreated fish were made to en-
sure that the fish was free from medicine. 
In order to get an end-concentration of about 400 µg/kg of flumequine and 200 µg/kg of 
oxolinic acid in the fish material before freeze-drying, the proper amount of muscle/skin of 
untreated fish to be added to the treated fish was calculated. 
In practice, two mixtures of muscles and the corresponding skin containing the double con-
centration of the desired end value were stored. Previous to storage, a definite amount of un-
contaminated fish was added to fish with a well-known content of oxolinic acid to obtain the 
desired concentration in the mixtures. In the same way a mixture of flumequine-containing 
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fish was added to uncontaminated fish to obtain the desired concentration before storage. In 
such a way two mixtures were obtained, one containing about 800 µg/kg of flumequine and 
the other about 400 µg/kg of oxolinic acid. Equal amounts of the two mixtures were mixed 
and homogenized to obtain the desired concentrations. 
During the preparation of the material, a skin-to-muscle ratio of 1:9 was used. The calculated 
amount of skin to be added was treated separately. This procedure applied to skin from both 
treated and untreated fish. 
A weighted amount of skin, 10 g, was cut into small pieces with a pair of scissors. The mate-
rial was transferred to a blender and 200 mL of distilled water was added. It was homoge-
nized for 3 x 5 minutes and sifted through a sieve (pore size 0.5 mm). Afterwards the blender 
was flushed and the mixture was sifted 3 times using 10 mL of water each time. The amount 
of treated and untreated fish contained in the 10 g of skin was calculated in advance. This 
ratio was calculated on the basis of the results from the analyses which were carried out on 
treated and untreated fish to begin with. 
Afterwards a definite amount of muscle (e.g. 90 g of muscle if the skin fraction constitutes 10 
g) was taken. The sample was cut into pieces, approximately 3 x 3 cm, and was transferred to 
a blender. The ratio of treated to non treated fish to be employed was calculated beforehand. 
The homogenized skin fraction of 10 g with water was subsequently added to the blender. 
This means that the blender contained a certain amount of oxolinic acid per g of fish (e.g. 
about 400 ng of oxolinic acid per g of wet weight) where the ratio between muscle and skin is 
9:1. 
The same procedure was carried out on flumequine-containing material, and equal amounts of 
the two mixtures were then mixed in the blender. 
After homogenization all the material was sifted through a sieve (pore size 0.5 mm) to remove 
residues of connective tissue and other particles. At this stage the material was a liquid homo-
geneous mixture containing a lot of water. It was necessary to homogenize the fish skin. The 
liquid mixture was subsequently distributed in 250 mL plastic bottles – 100 mL in each. The 
bottles were frozen horizontally (to have a large surface) at –80 °C for 6 hours. Afterwards 
they were placed in a freeze-drier. The freeze-drying process lasted 7 days. Eventually the 
contents of all bottles were pressed through a sieve with a pore size of 0.5 mm, transferred to 
a homogenizer and homogenized for 2 x 5 minutes. 
 
4.2 Bottling of samples 
Totally 3.2 kg of freeze-dried material was produced for the certification. The material packed 
in dry ice was sent to European Commission DG Joint Research Centre, Institute for Refer-
ence Materials and Measurements, IRMM, (Geel, Belgium) in February 2002. 
The final homogenization and bottling were done at IRMM. All salmon was homogenized for 
1 hour in a Turbula mixer. A total number of 1400 units were bottled with 2.2 g powder in 
amber glass vials. After a vacuum treatment and filling with argon, the vials were closed with 
PTFE protected rubber stoppers and finally sealed with an aluminium cap. The last day of 
bottling (= production day) was 13-03-2002. Ten representative samples were taken for Karl 
Fisher water determination. The mean of the moisture content was calculated as 2.20% ± 
0.14% and the water activity as 0.12 ± 0.01. 
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Particle size measurements have been carried out on bottles 0023, 0303, 0583, 1003 and 1283. 
The particle size distribution peaked at 200 µm with a top particle size of < 515 µm. 
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Figure 2 - Particle size distribution of freeze-dried material in bottles. 
 
4.3 Dispatching of samples 
Samples were dispatched to DTI for homogeneity and stability studies. 
For the certification exercise 14 samples were dispatched to each of the 15 participants. Two 
separate vials closed with a screw cap, marked A and B, of evaporated spiked fish extract 
were also sent to the participants. These samples were supplied by Yndestad, NCVM, and 
spiked with oxolinic acid and flumequine. They were prepared analogously as described in 
section 3.4. 
All these samples were packed in special containers filled with dry ice and dispatched within 
24 hours by a private courier to the various laboratories. 
 
5. TESTING OF THE MATERIAL 
5.1 Homogeneity study 
40 samples, out of all 1400 bottles, were selected for the evaluation of the between-bottle and 
within-bottle homogeneity. The samples were selected by IRMM to represent the whole pro-
duction and had previously been stored at –80 °C. 
From each bottle 2 sub-samples were analysed under repeatability conditions. Sample intake 
was 1.00 g.  
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5.1.1 Analytical method used for the homogeneity tests 
The analytical work for homogeneity test and stability test for certification samples was done 
using the method described in [1], including 5 min in ultrasonic bath for the extraction. Detec-
tion limits were 10 µg/kg for flumequine and 5 µg/kg for oxolinic acid. 
5.1.1.1 Extraction technique 
1 g of freeze-dried material was reconstituted with 2 mL of water. 1 mL of 25% w/w NH3 and 
6 mL of acetonitrile were added. The sample was mixed for 1 min in a whirly mixer and 5 
min in an ultrasonic bath. The homogenate was centrifuged and 3 mL of 5 mol/L NaCl was 
added to 5 mL of supernatant. To the lower layer were added 1 mL of 85% w/w H3PO4 and 4 
mL of CHCl3. After mixing and centrifugation, CHCl3 was evaporated and the residue redis-
solved in the mobile phase. 
5.1.1.2 HPLC analysis 
The chromatographic separation of the quinolones was performed on a programmable HPLC 
system with a fluorescence detector and a 3 µL flow cell. 
HPLC conditions were: 
 
- Column:   Phenomenex, Ultracarb, 5 ODS; 
- Gradient eluent:  A: 0.02 mol/L H3PO4/Acetonitrile/Tetrahydrofurane 
(650/200/150, v/v/v); 
B: Acetonitrile/H2O (60/40, v/v); 
- Column temperature:  25 °C; 
- Injection volume:  50 µL; 
- Flow rate:   0.8 mL/min; 
- Fluorescence detection: Excitation: 325 nm; Emission: 360 nm. 
 
Calibration was performed with flumequine and oxolinic acid supplied by Sigma-Aldrich (St. 
Louis, MO, USA). Stock solutions of flumequine were prepared in acetonitrile/H2O, (50/50, 
v/v) and of oxolinic acid in 0.5 mol/L NaOH. Working solutions were prepared in mobile 
phase. Correction was made for water content (1.7 % w/w) and recovery (82.4 % for flume-
quine and 81.0 % for oxolinic acid). 
 
5.1.2 Results 
The results of the homogeneity study are given in table 2.  
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Table 2 - ANOVA table for homogeneity of flumequine and oxolinic acid. Measurement unit: µg/kg. 
 Source of varia-
tion 
SS d.f. MSq St. dev. F 
Between Units 70,281.564 39 1,802.091 15.678 1.375 
Within Units 52,418.685 40 1,310.467 36.200  Flumequine 
Total 122,700.249 79    
Between Units 22,544.519 39 578.065 10.868 1.691 
Within Units 13,673.845 40 314.846 18.489  Oxolinic acid 
Total 36,218.364 79    
 
The measurements showed no relevant inhomogeneity among the samples. 
 
5.2 Stability study 
The isochronous layout for stability studies was applied to both analytes in BCR-725. Storage 
of samples was started in May 2002, immediately after the production of 1400 samples. The 
reference temperature for this study was –80 °C. At this temperature no impact on the analyte 
contents over a long time period can be expected. The analytical method used is analogous to 
the method used for the homogeneity study. 
 
5.2.1 Short-term stability study 
5.2.1.1 Design of the short-term stability study 
The stability study mentioned in section 3.4 was done on material that essentially was the 
same as the BCR-725 material. The results of this study are complemented with additional 
data obtained as part of the stability study on the BCR-725 material produced in 2002. First 
the old data will be presented and subsequently the new data will be shown in the last para-
graph of section 5.2.1.2. 
The reference temperature in all cases was –80 °C.  
For the first stability study, a certain number of samples were stored at various temperatures:  
-18 °C, +4 °C and at room temperature in the dark. While the temperatures –18 °C and +4 °C 
were automatically kept constant, the room temperature varied from +20 °C to +30 °C. The 
study started on March 2001. 
All samples stored at the different temperatures were put back to the reference temperature,    
-80 °C, after a pre-determined time period (see table 3). 
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Table 3 - Analytical scheme for the short-term stability study. 
 Temperature in °C Number of analysed vials 
-80 6    
-18 2 3 3 3 
+4 3 3 3 3 
Storage 
temperature T 
Ambient T 3 3 3 3 
Duration of storage in weeks 21 6 2 1 
 
All 41 samples were analysed under repeatability conditions using the method described in 
[1] and not taking water content into account. Visually, alterations could be seen on vials 
stored at 20-30 °C after 150 days. The material in these vials had turned brownish, while ma-
terial in all other vials had maintained its original appearance. 
In the new study, a temperature of +40 ºC was chosen, and three measurements were per-
formed on time points 0, 1 and 2 months. 
5.2.1.2 Results of the short-term stability study 
The results of the first stability study are shown in figure 3 and 4. All analyte contents are 
given as relative contents corresponding to the average of the three measurements at tempera-
ture T, versus the average content for the six measurements of the reference sample (stored at 
–80 °C for 21 weeks). The value of 1.0 for the reference temperature of –80 °C shows the 
uncertainty of the method. In figure 3 and 4 the relative contents are plotted versus the storage 
time in weeks. 
The results are also shown in tables 4 and 5 where: 
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Figure 3 - Results of short-term stability study, flumequine 
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Figure 4 - Results of short-term stability study, oxolinic acid 
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Table 4 - Ratio of means, flumequine. Measurements are expressed in µg/kg 
Weeks 0 1 2 6 21 
R(-18) ± U(-18) 1.000 ± 0.033 1.050 ± 0.030 0.998 ± 0.056 0.985 ± 0.023 0.973 ± 0.021 
R(+4) ± U(+4) 1.000 ± 0.033 1.017 ± 0.028 1.019 ± 0.033 0.968 ± 0.032 1.020 ± 0.028 
R(25) ± U(25) 1.000 ± 0.033 0.965 ± 0.082 1.016 ± 0.031 0.995 ± 0.030 0.981 ± 0.044 
 
 
Table 5 - Ratio of means, oxolinic acid. Measurements are expressed in µg/kg 
Weeks 0 1 2 6 21 
R(-18) ± U(-18) 1.000 ± 0.040 1.061 ± 0.032 1.017 ± 0.056 0.988 ± 0.026 0.979 ± 0.036 
R(+4) ± U(+4) 1.000 ± 0.040 1.026 ± 0.037 1.031 ± 0.031 0.963 ± 0.036 1.024 ± 0.028 
R(25) ± U(25) 1.000 ± 0.040 0.977 ± 0.088 1.027 ± 0.031 1.006 ± 0.029 0.974 ± 0.047 
 
From T = -80 °C measurement the RSD of the method was calculated: 
 
- RSD flumequine:  2.3 % 
- RSD oxolinic acid:  2.8 % 
 
The slopes corresponding to the data obtained at each temperature considered were calculated 
for both compounds. No statistically significant trend was observed according to the trend 
analysis described in [7], therefore no instability was associated to the flumequine and the 
oxolinic acid content of BCR-725. All relative contents, determined within the temperature 
range of interest and over the whole time period, are within the range of measurement uncer-
tainty of the reference sample. A slight decrease of contents at room temperature is observed 
for both quinolones, but not outside the 5% and 1% uncertainty range. 
The short-term stability study at +40 ºC, performed in 2002, gave as a result the data shown in 
Table 6 and 7, which are illustrated in Figures 5 and 6. The statistical evaluation on the slopes 
of the regression lines revealed a significant trend only in the case of flumequine. 
 
Table 6 - Ratio of means, flumequine.  
Weeks 0 1 2 
R(+40) ± U(+40) 1.000 ± 0.0035 0.943 ± 0.032 0.946 ± 0.027 
 
 
Table 7 - Ratio of means, oxolinic acid.  
Weeks 0 1 2 
R(+40) ± U(+40) 1.000 ± 0.041 0.955 ± 0.047 0.954 ± 0.029 
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 Figure 5- Results of short-term stability study 2002, flumequine. 
  Figure 6- Results of short-term stability study 2002, oxolinic acid. 
5.2.1.3 Conclusion on short-term stability  
Flumequine and oxolinic acid contents were determined to be stable over the whole time pe-
riod up to a temperature of +30 °C. No analyte losses outside the uncertainty level of the 
measurement (reference content at –80 °C) up to room temperature occurred. Oxolinic acid 
showed stability even up to +40 ºC. Based on these considerations and preventing from possi-
ble extreme conditions, it would be recommendable to refrigerate the reference material at 
least down to +4 ºC during the dispatch. 
 
 
5.2.2 Long-term stability study 
The long-term stability study was conducted over a period of 16 months, following an iso-
chronous design. Three samples were analysed at temperatures of –18 ºC, +4 ºC and +21 ºC 
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ºC and at time points 0, 4, 8 and 16 months. The reference temperature employed was –80 ºC. 
The results obtained for flumequine and oxolinic acid, expressed as ratios, are illustrated in 
Tables 8 and 9, respectively. 
 
Table 8 - Ratio of Means for flumequine concentrations, R(T)=XT/Xref ± Uncertainty(T). Time in months 
 0 4 8 16 
R(-18) ± U(-18) 1.000 ± 0.035 0.961 ± 0.035 0.949 ± 0.032 0.952 ± 0.027 
R(+4) ± U(+4) 1.000 ± 0.035 0.950 ± 0.029 0.907 ± 0.067 0.918 ± 0.050 
R(+21) ± U(+21) 1.000 ± 0.035 0.968 ± 0.026 0.922 ± 0.030 0.908 ± 0.045 
 
Table 9 - Ratio of Means for oxolinic acid concentrations, R(T)=XT/Xref ± Uncertainty(T). Time in months  
 0 4 8 16 
R(-18) ± U(-18) 1.000 ± 0.041 0.969 ± 0.040 0.961 ± 0.033 0.960 ± 0.029 
R(+4) ± U(+4) 1.000 ± 0.041 0.961 ± 0.041 0.962 ± 0.037 0.949 ± 0.051 
R(+21) ± U(+21) 1.000 ± 0.041 0.983 ± 0.032 0.927 ± 0.030 0.935 ± 0.051 
 
The statistical evaluation of the slope was performed for each temperature individually, -18 
ºC, +4 ºC and +21 ºC. The calculations were carried out taking into account all the individual 
measurements included within the ratio values showed in Tables 8 and 9. The trends were 
found not significant either for flumequine or for oxolinic acid at each temperature consid-
ered. However the comparison of the negative slope values between different temperatures 
indicates an increase in the absolute value of the slope with the increase in temperature, which 
suggests certain level of degradation of the material.  
A significant trend of the slope at the 95% confidence level was found when all individual 
measurements, regardless the temperature, were plotted as a single regression line versus 
time. Again, this is an indication of certain degree of degradation of the material, as already 
suggested. As a consequence, an additional uncertainty, which covers the possible maximum 
degradation during the shelf life of the material, is included as a contribution to the long-term 
stability uncertainty (see section 8.1.). 
Due to the slow degradation rate observed, even at a temperature of –18 ºC, a long-term stor-
age temperature of –70 ºC is established. As a preventive measure and waiting for the final 
assessment on the stability of the material, samples were kept at –70 ºC, from the finalisation 
of the production to the present time, to avoid any possible degradation.  
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6. CERTIFICATION MEASUREMENTS 
Measurements for the certification exercise were performed according to the BCR Guidelines 
[4]: 
- At least six independent measurements of flumequine and oxolinic acid content had to 
be performed, at least spread over two different days. 
- The water content had to be determined the same day as the analyte measurements 
from the same bottle, but on a separate test portion. 
- A blank determination had to be made at each day of analysis. 
- The following materials and quantities were distributed for the certification of BCR-
725: 
? 14 bottles of approximately 2.2 g of BCR-725 
? 1 vial of evaporated spiked extract containing known amounts of flumequine and 
oxolinic acid. 
? 1 vial of evaporated spiked extract containing unknown amounts of flumequine 
and oxolinic acid. 
 
The analytical methods used for the determination are described in detail in section 6.6. Each 
laboratory used its own optimized procedure for sample preparation, extraction, clean up 
(where appropriate), method of injection, chromatographic separation and detection. These 
methods were optimized after the feasibility study. All procedures and measurements were 
recorded and reported by each laboratory according to a given protocol in reporting sheets 
provided by the co-ordinator of the study.  
Twelve of the participating laboratories delivered the results in the framework of the certifica-
tion exercise. One laboratory withdrew from the exercise, and another laboratory withdrew 
flumequine results. 
 
6.1 Calibration standards 
Each laboratory prepared separate calibration solutions according to its own laboratory proce-
dures. These solutions were used for calibrating the relevant detector within its dynamic 
range. 
The calibration solutions were prepared from chemicals from Sigma-Aldrich, Fluka and ICN, 
and taking purity into account. Being pharmaceutical products, certificates of analysis for the 
particular lot number of the chemicals were available with purities and other informations. 
Different lot numbers were used, and neither with FLD nor with MS, peaks from impurities 
were detected. 
 
6.2 Internal standards 
No laboratories reported use of internal standards. 
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Table 10- Purity of flumequine calibrant 
Lab. code % C 
(~ % Purity) 
% N 
(~ % Purity) 
% Purity 
HPLC 
% Purity 
Titration 
% Purity 
Used in calculations 
0   95,7 98,6 97,2 
1   94,6 100,7 94,6 
2   94,6 100,7 100 
3 64,2 (99,7) 5,4 (100) 99,9  99,9 
4 64,2 (99,7) 5,4 (100) 99,9  99 
5 64,2 (99,7) 5,4 (100) 99,9  99,9 
6 64,2 (99,7) 5,4 (100) 99,9  99,9 
7   94,6 100,7 94,6 
8 64,2 (99,7) 5,4 (100) 99,9  99,9 
9   99,9  100 
 
 
Table 11- Purity of oxolinic acid calibrant. 
Lab. Code % C 
(~ % Purity) 
% N 
(~ % Purity) 
% Purity  
Thin Layer 
Chromatography 
% Purity 
Titration 
% Purity 
Used in calculations 
0 59,7 (100) 5,4 (100) > 99  100 
1 60,0 (100) 5,4 (100) > 99  100 
2 59,7 (100) 5,4 (100) > 99  100 
3 59,65 (99,8) 5,33 (99,4) 99  98 
4 59,65 (99,8) 5,33 (99,4) 99  98 
5   99 100,5 99 
6 59,65 (99,8) 5,33 (99,4) 99  99 
7 59,65 (99,8) 5,33 (99,4) 99  99 
8 59,65 (99,8) 5,33 (99,4) 99  99 
9 59,7 (100) 5,4 (100) > 99  99 
10    > 97 100 
 
 
6.3 Calibration 
All standards and samples were prepared on a mass basis using calibrated balances. Working 
solutions were prepared by mass controlled dilution. Laboratories code 4 and 8 used dilutions 
by weight. The agreement of the measurement results of the laboratories was assessed using a 
”known” and ”unknown” sample of differing compositions. As a quality check of the calibra-
tion, the ”known” solution had to be measured by each participant before the measurements 
of the rest of the samples. 
The dynamic range of the detector was established for each analyte individually from calibra-
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tion solutions of different concentrations. The dynamic range of the detector is defined as the 
range where the detector response per mass unit versus the mass injected shows a linear re-
sponse. At least 4 calibration points had to be used. The calibration of the detector was veri-
fied at least once in a sequence of injections on each measurement day. 
 
6.4 Analytical blanks 
Analytical blanks were performed at each day of analysis. All solvents used were of the high-
est purity grade. 
 
6.5 Determination of the water content 
The water content was determined by heating in an oven at a temperature of 102 °C or 105 °C 
until constant weight. The reported mean water contents for eight samples ranged between 1.0 
and 3.3 % w/w with an overall mean of 2.0 % w/w. 
In agreement with BCR Guidelines [4] the analyte contents determined in the certification 
exercise were corrected for the water content as reported by the participants. 
 
Table 12 - Water content in the eight freeze-dried samples. 
Lab code Water content, % w/w, used for result calculation of eight samples Mean Std. 
dev. 
0 1,7 1,6 1,7 1,8 1,8 1,6 2,0 1,7 1,8 0,1 
1 2,4 1,9 2,3 2,2 2,0 2,2 2,2 2,6 2,3 0,2 
2 1,8 1,8 1,8 1,9 1,9 1,9 1,8 1,7 1,8 0,1 
3 2,4 2,4 2,3 2,5 2,1 2,1 2,0 2,5 2,3 0,2 
4 2,0 2,0 2,0 2,2 2,4 2,2 1,8 1,6 2,0 0,3 
5 1,0 1,7 1,5 1,0 1,6 1,7 1,4 1,6 1,5 0,3 
6 3,4 2,8 3,3 3,2 3,3 3,5 2,8 4,3 3,3 0,5 
7 2,5 2,4 2,2 1,8 2,1 5,3 1,4 6,4 3,0 1,8 
8 1,8 1,7 2,0 1,8 1,9 2,1 2,0 2,0 1,9 0,1 
9 0,9 0,9 1,4 1,1 1,0 1,2 1,2 0,9 1,1 0,2 
10 1,8 1,4 1,5 1,0 1,0 1,8 1,6 1,9 1,5 0,4 
 
6.6 Analytical methods used for certification 
The analytical procedures used for the determination of analyte contents in BCR-725 consist 
in four distinct steps of analytical work: 
1. Sample preparation and extraction 
2. Sample clean up 
3. Chromatographic separation by HPLC 
4. Calibration and detection 
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6.6.1 Sample preparation and extraction 
The evaporation of centrifugate liquid used for clean up is listed in table 13. 
Participants adjusted the solvent extraction step following conclusions drawn from the feasi-
bility study, where all solvents and extraction procedures used were evaluated for their extrac-
tion efficiency (reproducibility and recovery). Most laboratories used reconstitution of the 
freeze-dried material by adding 2 parts of water. The extraction solvents and extraction times 
applied are listed in table 13. 
 
Table 13 - Preparation of centrifugate liquid 
  Extraction solvent    
Lab. code Reconstitution Type Amount Extraction Extraction time Centrifugation time 
0 1 g sample + 2 g water, M Acetonitrile + 
25%w/w NH3 (6+1) 
7 mL V,U 6 min. 3 min. 
1 1 g  sample + 2 g water 
C : 10 min., M 
C : 10 min. 
Acetonitrile + buffer, 
pH 9.1 (2+3) 
1 mL U,V 3 min. 3 min. 
2 1 g sample + 2 g water, M 
C : 15 min. 
0.5 mol/L NaOH + 
67%w/w acetone in 
water (1+4) 
5.5 mL H,U,C,V 3 hours 10 min. 
3 0.5 g  sample + 2 mL  
0.2 mol/L HCl 
Ethyl acetate 2 x 4 mL  
and  2 mL 
3 x HH 3 x 10 min. 3 x 5 min. 
4 0.5 g sample 0.05 mol/L potassium 
phosphate buffer pH 
7.4 
3 x 10 mL 3 x U 3 x 10 min. 3 x 5 min. 
5 1 g sample + 2 mL water 
C : 15 min. 
Ethyl acetate 2 x 10 mL 2 x V 2 x 1 min. 2 x 5 min. 
6 1 g sample + 2 mL water + 1 mL 
of (0.002 mol/L 
H3PO4/acetonitrile/tetra-
hydrofuran, 64 /21/15, v/v/v) 
Acetone + 25%w/w 
NH3 (5+1) 
6 mL H,U,C,V 16 hours 5 min. 
7 1 g sample + 2 mL  water, V, C : 
1 hour 
Acetonitrile + 25% 
NH3 (6+1) 
7 mL V,U,C,V 16 hours 10 min. 
8 0.5 g sample + 1 mL water, M Dichloromethane 2 x 10 mL 2 x (M,C) 2 x 5 hours 2 x 10 min. 
9 1 g sample + 2 g water, H Methanol 5 mL 2 x (M,C,H) 1 x 12 hours + 
2 min. 
2 x 10 min. 
10 1 g sample + 2 g water, M Ethyl acetate 2 x 10 mL 2 x V 2 x 10 min. 2 x 10 min. 
C =    Contact time, standing 
H =    Ultraturrax 
HH = Homogenisation with Heidolph 
M =   Mix, manually 
U =    Ultrasonication 
V =    Vortex 
 
6.6.2 Clean-up 
Clean-up of extracts did range from protein precipitation + centrifugation to several back ex-
tractions or use of C18-cartridge. The techniques applied are included in table 14. 
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Table 14 - Preparation of solution to inject into HPLC from centrifugate liquid. 
Lab. code Clean-up 
0 5 mL supernatant was mixed with 3 mL 5 mol/L NaCl, and centrifugated 1 min. Lower layer was mixed with 1 mL 85%w/w 
H3PO + 4 mL chloroform. After centrifugation the chloroform phase was evaporated at 10 °C under N2 stream. The residue was 
re-dissolved in 3 mL mobile phase and injected after filtration through 0.5 µm cellulose acetate filter. 
1 Supernatant was evaporated at 50 °C under N2 for 15 min. 0.5 mL buffer, pH 9.1 + 300 µl hexane was added. V: 20 sec. Cen-
trifugation 3 min. and lower phase injected. 
2 1 mL supernatant was mixed with 1 mL acetonitrile. V, C: 10 min. (protein precipitation). After centrifugation 10 min. the 
upper phase was injected. 
3 Combined supernatants were mixed with 4 mL 1 mol/L NaOH. HH: 10 min. and centrifugation 5 min. Repeated, and combined 
aqueous phase was mixed with 1 mL 85%w/w H3PO4. 3.5 mL chloroform was added,  HH: 10 min. and centrifugation 5 min. 
Repeated, and combined chloroform phase was evaporated at 40 °C under N2 stream. The residue was redissolved in 1 mL 
mobile phase and injected. 
4 Combined supernatants were filtered through 2 µm filter and 15 mL loaded on a conditioned Discovery C18 cartridge. After 
wash with 3 mL water the quinolones were eluted with 5 mL of a mixture of methanol and 25%w/w NH3 (75/25, v/v). The 
eluate was evaporated under N2 stream (< 50 °C). The residue was redissolved to 1.0 g with 0.05 mol/L potassium phosphate 
buffer, pH 7, before injection. 
5 Combined supernatants were evaporated at 45 °C under N2 stream. The residue was redissolved in 2 mL mobile phase (V: 1 
min., U: 3 min.) and 2 mL hexane. V: 1 min. Centrifugation 5 min., and injection after discarding upper hexane phase. 
6 1 mL supernatant was mixed with 0.5  mL 3 mol/L H3PO4 and 1.0 mL acetone was added. V and centrifugation 3 min. 1 mL 
supernatant was mixed with 1 mL water, and injected after filtration through Spin-X-filter and centrifugation 5 min. 
7 2.5 mL supernatant was mixed with 3 mL hexane. V, centrifugation and hexane phase removed. The other phase was evapo-
rated at 50 °C under N2 stream. The evaporated sample was redissolved in 0.5 mL mobile phase and injected after filtration 
through Spin-X-filter. 
8 Combined organic phases were back-extracted with 5 mL 0.01 mol/L NaOH. After centrifugation the acqueous phase was 
injected. 
9 Combined supernatants were mixed with 2 mL 0.1 mol/L NH3 + 2 mL hexane. After centrifugation 10 min. hexane phase was 
discarded. Hexane washing was repeated 2 times. Residual phase was reduced to approx. 2 mL with a rotary evaporator. 6 mL 
ethyl acetate was added, and after centrifugation 10 min. the upper phase was evaporated to dryness using rotary evaporator. 
The residue was redissolved in mobile phase and injected. 
10 Combined supernatants were filtered and evaporated at 50 °C under N2 stream. The residue was dissolved in 2 mL 0.01 mol/L 
oxalic acid, pH 3, and washed with 2 mL hexane. Aqueous layer was filtered before injection. 
C =    Contact time, stading 
HH = Homogenisation with Heidolph 
V =    Vortex 
 
6.6.3 High performance liquid chromatography 
The HPLC conditions as used by the participants are summarized in tables 15, 16 and 17. 
 
Table 15 - HPLC conditions, I. 
Lab. Code Analytical column 
0 Phenomenex, ultracarb, 5 ODS 
1 PLRP-S-100, 5 µm, 150 x 4.6 mm 
2 Phenomenex C18 ultracarb 5 ODS (30) 150 x 4.60 mm, 5 micron 
3 PuroSpher 180 RP-18 E 125 x 4 mm i.d., 5 µm particle size + guard column 4 x 4 mm i.d.  (Merck) 
4 Symmetry C18, 5 micra, 4.6 x 150 
5 Lichrosorb RP-8, 5 µm, 250 mm x 4.6 mm + guard-column. All-Guard C8, 5 µm,  
7.5 mm x 4.6 mm 
6 PLRS 15 cm x 4.6 mm, 5 mm 
7 PLRP-S, 100Å, 5 µm, 150 x 4.6 mm 
8 Inertsil C8 (150 x 4.6 mm) + guard column Inertsil C8 
9 Phenomenex aqua 250 x 3 mm 
10 Lichrospher 60 RP – select B (5 µm) Merck 
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Table 16 - HPLC conditions, II 
Lab. code Mobile phase 
0 A : 0.02 mol/L H3PO4/acetonitrile/tetrahydrofurane (650/200/150, v/v/v) 
B : Acetonitrile/H2O (60/40, v/v) 
1 0.02 mol/L H3PO4/acetonitrile/tetrahydrofurane (72/16/12, v/v/v) 
2 0.02 mol/L phosphoric acid (pH = 2.5)/acetonitrile (55/45, v/v) 
3 Orthophosphoric acid solution 0.02 mol/L (67%) /acetonitrile (67/33, v/v) 
4 Acetonitrile/0.02 mol/L phosphate buffer pH 3.0 (34/:66, v/v) 
5 Oxalic acid 0.01 mol/L at pH 3/acetonitrile (60/40, v/v) 
6 0.01 mol/L H3PO4 / acetonitrile/ tetrahydrofurane  (64/21/15, v/v/v) 
7 0.02 mol/L H3PO4 /acetonitrile/tetrahydrofurane /62.5/ 22.5/15.0, v/v/v) 
8 0.01 mol/L oxalic acid/acetonitrile (55/ 45, v/v) 
9 0.01 mol/L oxalic acid/methanol (30/70, v/v) 
10 Acetonitrile/N,N-dimethylformamide/0.01 mol/L oxalic acid  (27/6/67, v/v/v) 
 
Table 17 - HPLC conditions, III 
Lab. code Amount injected (µl) Flow rate (mL/min.) Column temp. (°C) Column in thermostated oven 
0 50 0.8 25 + 
1 100 0.8 50 + 
2 20 0.8 30 + 
3 10 0.8 27 + 
4 20 1 Room temperature + 
5 50 1 Room temperature - 
6 50 0.7 Room temperature - 
7 20 1 30 - 
8 20 1.5 Room temperature + 
9 5 0.35 35 - 
10 20 1 40 + 
 
6.6.4 Detection 
Most laboratories used fluorescence detection with a linear range defined by at least 4 calibra-
tion standards. 
Table 18 - Wavelengths used for fluorescence detection and linear calibration range. 
Lab. code Exitation wavelength 
(nm) 
Emission wavelength 
(nm) 
Linear calibration  
range, flumequine 
µg/kg dry tissue 
Linear calibration 
range, oxolinic acid 
µg/kg dry tissue 
Number of calibration 
standards used 
0 325 360 2400 2200 5 
1 320 360 1800 1800 4 
2 325 360 5000 2500 6 
3 325 365 5000 5000 6 
4 312 366 8000 8810 5 
5 327 369 1200 1200 7 
6 325 360 4000 2000 6 
7 325 380 3000 3000 6 
8 328 365 4000 4000 6 
9 - - 4000 4000 7 
10 246 360 - 500 5 
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Laboratory code 9 used mass spectrometry for detection and a 7-points calibration. MS condi-
tions were: 
- Ionisation: Electrospray, positive mode 
- Ions:  262.1 (MH) and 244.0 (MH-H2O); SIM scan mode 
 
6.7 Recovery experiments 
All participating laboratories were requested to perform recovery experiments in order to ob-
tain quantitative information on the extraction efficiency and recovery after clean-up. The 
method of standard addition was applied to obtain recovery data. The spiked amounts should 
equilibrate with the fish material for 1 hour at least. Recovery figures were used to calculate 
the final results. 
The recommended method of standard addition involved spiking of the freeze-dried material 
at four different levels of analyte concentration: at 50, 100, 150 and 200 % of the target value 
of these analyte content. Recovery figures were calculated by means of linear regression. 
Recovery figures are shown in table 19. Recovery experiments were made on different days. 
Two laboratories used the same day recovery to correct for the final result, and nine laborato-
ries used recovery based on all recovery measurements in the final result calculation. 
 
Table 19 - Recovery % and standard deviation of the recovery range %. 
 Flumequine Oxolinic acid 
Lab. 
code 
R1 ±  
Std.dev. R1 
R2 ± 
Std.dev.R2 
R(1+2) ± 
Std.dev. R(1+2)
R1 ±  
Std.dev. R1 
R2 ± 
Std.dev.R2 
R(1+2) ± 
Std.dev. R(1+2)
0   82,4 ± 3,1   81,0 ± 2,6 
1 96,4 ± 2,8 97,8 ± 6,0  100,2 ± 4,3 105,3 ± 3,8  
2 67,8 ± 0,5 67,1 ± 0,8  67,9 ± 0,5 66,8 ± 0,7  
3   100,1 ± 0,9   100,5 ± 1,2 
4   94,2 ± 2,2   86,2 ± 1,7 
5   91,4 ± 2,3   99,6 ± 2,9 
6   84,6 ± 6,7   98,7 ± 4,1 
7   53,2 ± 1,8   56,9 ± 1,0 
8   85,5 ± 3,4   92,9 ± 4,1 
9   82,2 ± 3,1   86,9 ± 3,3 
10      65,9 ± 2,7 
R1 = Recovery % day 1 
R2 = Recovery % day 2 
R(1+2) = Recovery % using experiments for both days. 
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7. TECHNICAL DISCUSSION 
The results of the certification study were discussed at an evaluation meeting of all partici-
pants on 23 September 2002. All steps of the procedure were reviewed in detail and the re-
spective data were carefully discussed and scrutinised.  
The outcome of this technical discussion of the results is summarised in the following para-
graphs: 
 
Need for a blank reference fish material 
During the technical discussion the potential need for a blank reference material was dis-
cussed, e.g. as produced in case of similar reference materials for banned veterinary drug such 
as clenbuterol. However, it was felt, that it is easy to buy uncontaminated fish, which would 
be fit for this particular purpose. Moreover, the current MRL values for oxolinic acid and 
flumequine are significantly higher than the detection limits that can be achieved by the 
analytical techniques in the certification campaign, so there is no real need for such material. 
 
Water content 
Some results from laboratory code 7 were higher than the average level. However, according 
to proofs provided by the laboratory, all samples had been handled correctly, e.g. samples 
were taken to a desiccator to equilibrate to room temperature before opening. No technical 
reasons were found to reject the higher results and they were consequently kept for the estab-
lishment of the certified values. 
 
Extraction of the target compounds: 
The certification campaign showed that no correlation between the type of solvent used for 
extraction or extraction time and extraction yields was found. Nevertheless, it should be em-
phasised that good extraction yields require reconstitution of the freeze-dried material or re-
peated extractions with aqueous solutions. 
It could also be shown that extraction of freeze-dried fish material requires generally a shorter 
extraction time than extraction of fresh fish, where at least 5 hours’ extraction is required [3]. 
Recovery percentages as low as 50 were accepted provided that the uncertainty of the recov-
ery % (95 % interval) is within ± 10 % rel. 
Laboratory code 10 obtained a recovery % too low for flumequine and therefore withdrew 
those results. 
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8. EVALUATION OF UNCERTAINTIES AND CERTIFIED VALUES 
The evaluation of uncertainties in the context of certification exercises has evolved over the 
past decade. Nowadays, certified values should be accompanied by uncertainty statements in 
compliance with the requirements set by GUM [5]. While the design of new certification pro-
jects consider the needs for a proper estimation of the various uncertainty sources such as sta-
bility and homogeneity, older campaigns aimed only on qualitative statements (yes/no deci-
sions) whether a material was stable and homogeneous. 
The evaluation described hereafter is based on a concept described by Pauwels et al. [6 and 
literature cited] and uses available data discussed in the previous chapters. 
 
8.1 Uncertainty evaluation 
8.1.1 Conceptual considerations 
Based on the findings obtained in the stability and homogeneity studies as well as on the scat-
tering of results in the batch characterisation, estimates for ubb (homogeneity), ults (long-term-
stability) and uchar (batch characterisation) were obtained and combined according to the fol-
lowing equation: 
 
2222 charltsbbCRM uuuU ++⋅=  
 
Due to the selected transport conditions established for dispatch, the uncertainty constituent 
for short-term stability (usts) is negligible and consequently not included in the overall uncer-
tainty. The estimation of the other uncertainty sources is described below. 
 
8.1.2 Uncertainty source “homogeneity” 
The homogeneity study is exhaustively described in section 5.1 and results have been evalu-
ated by means of one-way ANOVA. From this data (Table 2), an estimation of ubb was de-
rived from the homogeneity study as described by Linsinger et al [7]. 
Values for u*bb and sbb were calculated accordingly: 
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where n is the number of replicates per unit and νMSwithin the degrees of freedom of MSwithin; 
and 
n
MSMS
s withinbetweenbb
−
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As a principle the higher value between sbb and u
*
bb is adopted as ubb. The results of these cal-
culations are shown in Table 20. 
 
8.1.3 Uncertainty source “stability” 
For both flumequine and oxolinic acid a slow degradation rate was observed upon storage of 
16 months, as described in section 5.2.2. At –18 ºC the slope of the regression line indicated 
an almost negligible degradation, therefore it was decided to use the data corresponding to 
this temperature for the estimation of the ults. These data was used and evaluated using the 
approach employed by Linsinger et al [7].  
The ults comprises two main contributions. A term due to the degradation mentioned above 
corresponding to a bias (ub1), calculated as a rectangular distribution of the slope (b). And a 
second term, which considers the uncertainty associated to such bias (ub2). The ults, within the 
chosen shelf life of the material (xshelf), is estimated as follows:  
 
Where, 
 
 
As a result ults values of 5.4 % for oxolinic acid and of 6.0 % for flumequine were calculated  
for a shelf-life of 36 months.  
 
8.1.4 Uncertainty source “batch characterisation” 
An estimate for uchar was derived from the standard error obtained on the mean of laboratories 
means. 
 
8.1.5 Uncertainty budget 
Based on the uncertainty contributions mentioned in sections 8.1.2 to 8.1.4 the following un-
certainty budget is established (Table 20):  
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Table 20 - Uncertainty budget for BCR-725 
 Oxolinic acid Flumequine 
ubb (sbb) [in rel. %] 1.82 1.34 
u*bb [in rel. %]
a 0.81 0.84 
ults [in rel. %] 7.35 8.59 
uchar [in rel. %] 1.80 1.73 
coverage factor k 2 2 
Shelf life [months] 36 36 
UCRM [in rel. %] 15.56 17.73 
Mean [in µg/kg] 596.91 1171.32 
Uncertainty [in µg/kg] 92.91 207.63 
Rounded according to ISO 
31-0 [8] and expressed in 
µg/kg 
600 ± 100 1170 ± 210 
a not used for combined uncertainty 
 
8.2  Certified values 
 
The certified flumequine mass concentration (dry mass) for BCR-725 is: 
 
1170 ± 210 µg/kg. 
 
The certified oxolinic acid mass concentration (dry mass) for BCR-725 is: 
 
600 ± 100 µg/kg. 
 
9. TRACEABILITY 
All measurements are traceable to HPLC. Different extraction, clean-up methods and two 
detection methods were employed, FLD and MS. 
 
10. INSTRUCTIONS FOR USE 
10.1 Transport and storage 
The reference materials are supplied in lyophilised form sealed under vacuum in brown glass 
vials. Shipment by postal services or carrier should be done using appropriate cooling ele-
ments. On receipt, the materials should be stored in the freezer. The materials can be handled 
as non-hazardous substances. 
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10.2 Recommendations for analysis 
As already mentioned in section 7 it should be emphasised that good extraction yields require 
reconstitution of the freeze-dried material or repeated extractions with aqueous solutions. Test 
portions of BCR-725 should therefore be treated accordingly. 
The homogeneity of BCR-725 was demonstrated at the sample intake of 1.0 g. The certifica-
tion study did show excellent results with sample intake of 0.5 g. Therefore, a minimum sam-
ple intake of 0.5 g is recommended. Extracts from BCR-725 should be prepared immediately 
before analysis, and should be prepared from reconstituted material, e.g. 1 g BCR-725 + 2 mL 
water. 
The water content of the reconstituted material is approximately equal to the water content in 
fresh fish. It has to be noticed that extraction of fresh fish may require more than 5 hours [3]. 
Determination of the minimum fresh fish extraction time for the particular analytical method 
used is recommended. 
If the detection limits of the analytical method are high compared to the MRL values, it may 
be necessary to prepare and analyse in-house blank fish material. 
BCR-725 has a water content of approximately 2 % w/w. Whether BCR-725 is stored at fro-
zen conditions, or at 4-6 °C, the bottles should be taken to a desiccator to equilibrate to room 
temperature before opening. 
 
10.3 Use of the certified values 
This material may be used to check the precision and the trueness of the laboratory measure-
ment process according to ISO Guide 33 [9]. 
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12. ANNEX – TABLE OF INDIVIDUAL RESULTS AND GRAPHICAL 
PRESENTATIONS 
 
Table 21  - Mass fraction of flumequine – BCR - 725 (µg/kg) 
Lab  code (technique) Mean STDev H.W. CI 
(95%) 
Sample 
#1 
Sample 
#2 
Sample 
#3 
Sample 
#4 
Sample 
#5 
Sample 
#6 
Sample 
#7 
Sample 
#8 
0 (HPLC/FLD) 1,116.0 30.3 25.3 1,160.0 1,107.0 1,112.0 1,070.0 1,082.0 1,138.0 1,141.0 1,118.0 
1 (HPLC/FLD) 1,242.3 43.3 36.2 1,241.6 1,209.3 1,284.4 1,195.8 1,182.0 1,254.0 1,268.9 1,302.7 
2 (HPLC/FLD) 1,160.9 43.8 36.6 1,103.0 1,129.0 1,128.0 1,128.0 1,221.0 1,184.0 1,205.0 1,189.0 
3 (HPLC/FLD) 1,194.2 14.4 12.0 1,197.4 1,189.3 1,200.6 1,195.5 1,188.6 1,179.7 1,224.1 1,178.9 
4 (HPLC/FLD) 1,135.0 35.1 29.4 1,118.2 1,095.2 1,125.8 1,104.4 1,112.1 1,191.8 1,161.9 1,170.6 
5 (HPLC/FLD) 1,105.9 27.9 23.3 1,104.0 1,148.7 1,140.2 1,114.6 1,097.8 1,078.3 1,068.1 1,096.0 
6 (HPLC/FLD) 1,239.8 28.6 23.9 1,246.0 1,229.0 1,293.0 1,233.0 1,190.0 1,231.0 1,249.0 1,247.0 
7 (HPLC/FLD) 1,269.3 36.6 30.6 1,274.0 1,217.0 1,253.0 1,248.0 1,269.0 1,345.0 1,266.0 1,282.0 
8 (HPLC/FLD) 1,168.7 17.9 15.0 1,166.6 1,137.6 1,180.3 1,165.9 1,182.9 1,147.9 1,187.1 1,181.3 
9 (LC/MS) 1,081.1 35.3 29.5 1,107.0 1,118.0 1,024.0 1,070.0 1,069.0 1,110.0 1,042.0 1,109.0 
95% H.W. Confidence 
Interval 
45,7 
95% H.W. Tolerance 
Interval 
215,9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 – Mean values and CIs (95%) of  flumequine, expressed as mass fraction (µg/kg), obtained 
by the different participant laboratories.  Certified value and uncertainty are also shown.   
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Table 22 - Mass fraction of oxolinic acid - BCR - 725 (µg/kg). 
Lab. code Mean STDev H.W.  
CI 
(95%) 
Sample 
#1 
Sample 
#2 
Sample 
#3 
Sample 
#4 
Sample 
#5 
Sample 
#6 
Sample 
#7 
Sample 
#8 
0 554.3 14.9 12.4 578.0 554.0 554.0 533.0 535.0 565.0 561.0 554.0 
1 611.8 18.4 15.4 634.9 609.9 636.4 612.8 583.1 597.9 599.7 619.7 
2 588.3 23.4 19.5 553.0 575.0 569.0 572.0 610.0 610.0 610.0 607.0 
3 581.4 7.2 6.0 576.3 572.4 584.8 576.0 581.4 581.4 595.9 582.9 
4 563.6 22.7 19.0 565.7 594.1 568.4 558.9 552.1 594.3 547.6 527.5 
5 597.7 12.2 10.2 586.8 610.7 612.6 606.5 596.1 579.7 587.1 602.5 
6 610.0 17.4 14.6 630.0 622.0 634.0 613.0 586.0 597.0 601.0 597.0 
7 648.5 20.0 16.8 673.0 646.0 654.0 645.0 641.0 678.0 616.0 635.0 
8 578.8 19.1 16.0 591.9 582.2 564.2 598.4 603.7 546.9 567.5 575.5 
9 564.3 13.5 11.3 574.0 574.0 544.0 579.0 545.0 572.0 559.0 567.0 
10 667.3 22.9 19.1 705.0 665.0 698.0 666.0 640.0 654.0 661.0 649.0 
95% H.W. Confidence 
Interval 
23,9 
95% H.W. Tolerance 
Interval 
115,9 
 
 
 
 
Figure 6 – Mean values and CIs (95%) of oxolinic acid, expressed as mass fraction (µg/kg), obtained 
by the different participant laboratories.  Certified value and uncertainty are also shown.   
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Figures 
The length of the horizontal dotted bar corresponds to the 95% confidence interval. The verti-
cal dotted line features the certified value (average of laboratory averages). 
The laboratory code is followed by an indication of the detector used for analyte determina-
tion (for details, see list of abbreviations). 
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Abstract 
This report describes the preparation, homogeneity, stability and certification studies of a freeze-dried 
salmon tissue (BCR-725) certified for its contents of flumequine and oxolinic acid. A description of the 
analytical procedures used in the homogeneity and stability studies as well as in the certification study is 
included. All individual results of the certification study are reported. All relevant data from the 
homogeneity and stability studies and certification measurements are presented. 
The mission of the Joint Research Centre is to provide customer-driven scientific and technical 
support for the conception, development, implementation and monitoring of European Union 
policies. As a service of the European Commission, the JRC functions as a reference centre of 
science and technology for the Community. Close to the policy-making process, it serves the 
common interest of the Member States, while being independent of commercial and national 
interests. 
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